CASI Pharmaceuticals, Inc. (CASI) Earnings History
Annual and quarterly earnings data from 1994 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 39.1% | -138.8% | -137.6% |
| 2023 | 59.2% | -74.0% | -79.5% |
| 2022 | 63.3% | -61.5% | -95.1% |
| 2021 | 58.4% | -137.6% | -121.5% |
| 2020 | 37.2% | -348.6% | -318.9% |
Download Data
Export CASI earnings history in CSV or JSON format
Free sign-in required to download data
CASI Pharmaceuticals, Inc. (CASI) Earnings Overview
As of February 28, 2026, CASI Pharmaceuticals, Inc. (CASI) reported trailing twelve-month net income of -$49M, reflecting -0.3% year-over-year growth. The company earned $-3.08 per diluted share over the past four quarters, with a net profit margin of -1.4%.
Looking at the long-term picture, CASI's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2011.
CASI Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including UTHR ($1.33B net income, 0.4% margin), ZLAB (-$176M net income, -0.4% margin), AMRN (-$86M net income, -0.4% margin), CASI has room to improve margins relative to the peer group. Compare CASI vs UTHR →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
31 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$39M | -45.7% | -$40M | $-2.56 | -137.6% | -138.8% |
| 2023 | -$27M | +34.3% | -$25M | $-2.02 | -79.5% | -74.0% |
| 2022 | -$41M | -11.9% | -$26M | $-3.01 | -95.1% | -61.5% |
| 2021 | -$37M | +24.1% | -$42M | $-2.69 | -121.5% | -137.6% |
| 2020 | -$48M | -6.4% | -$53M | $-4.37 | -318.9% | -348.6% |
| 2019 | -$45M | -65.1% | -$40M | $-4.80 | -1098.1% | -968.1% |
| 2018 | -$27M | -155.1% | -$27M | $-3.24 | - | - |
| 2017 | -$11M | -13.9% | -$11M | $-1.75 | - | - |
| 2016 | -$9M | -31.2% | $9M | $-1.69 | - | - |
| 2015 | -$7M | +72.5% | $7M | $-2.22 | -15104.0% | 14990.8% |
See CASI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CASI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CASI vs AGIO
See how CASI stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CASI growing earnings?
CASI EPS of $-3.08 reflects slowing growth at -0.3%, below the 5-year CAGR of N/A. TTM net income is $-49M. Expansion rate has moderated.
What are CASI's profit margins?
CASI Pharmaceuticals, Inc. net margin is -1.4%, with operating margin at -1.4%. Below-average margins reflect competitive or cost pressures.
How consistent are CASI's earnings?
CASI earnings data spans 1994-2024. The current earnings trend is -0.3% YoY. Historical data enables comparison across business cycles.